Welcome to the era of mindful medicine.
Psilera Greenlit to Initiate
Phase 2 of NIH SBIR Grant
for Alcohol Use Disorder
Psilera
At A
Glance
-
We have created and developed six separate serotonergic compound families.
-
Two patents have been issued from the USPTO covering over 1 million novel compounds.
-
The Psilera leadership team has over 125 years of combined experience in the biotech and pharmaceutical industries.
-
Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.
-
Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.
Psilera is revolutionizing how small-molecule drug discovery is done. We pioneer & engineer novel therapies through next-generation precision neuroscience.
Our neuroplastogen-focused pipeline offers a spectrum of solutions to meet the evolving needs of patients.
UPCOMING EVENTS
UPCOMING EVENTS
Nov. 16 - 19
London
Jefferies Global Healthcare Week
Co-Founders Chris Witowski, PhD, and Dr. Jackie von Salm will travel across the pond to meet with key development partners and investors from throughout Europe. While in London, they will focus on advancing the PSIL-006 clinical program through focused discussions with new and established pharmaceutical connections. If you will be in London for the event and would like to learn more, message us at info@psilera.com.
Jan. 10
San Francisco, CA
Feb. 4 - 5
Washington, D.C.
Neuroscience Innovation Forum
Co-founders Chris Witowski, PhD, and Dr. Jackie von Salm will speak and present at the 10th Annual Neuroscience Innovation Forum. Dr. von Salm will share her unique perspective on the Psychedelics 2027 Panel: Where Does the Field Stand? Dr. Witowski will share the latest developments from Psilera in a company presentation.
ACI’s Summit on Controlled Substances
Dr. Jackie von Salm will speak on the panel, “Accelerating Psychedelic Therapeutics: Interagency Policy Briefing and Implementation Challenges for the 2026 Executive Order,” at the American Conference Institute’s 8th Annual Summit on Controlled Substances: Regulation, Litigation, and Enforcement.